$COAG News

Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60

Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate

Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Hemab Therapeutics Presents Clinical, Preclinical Data From Sutacimig In Glanzmann Thrombasthenia And Factor VII Deficiency At International Society On Thrombosis And Haemostasis 2026 Congress

Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

Hemab Advances Bleeding Disorder Pipeline

CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55

Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target

HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52

Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

HC Wainwright & Co. Reiterates Buy on Hemab Therapeutics Hldgs, Maintains $40 Price Target

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

Hemab Therapeutics To Present Clinical And Preclinical Data From Multiple Blood Coagulation Programs At ISTH 2026 July 11-15

HC Wainwright & Co. Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $40

Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Wedbush Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $42